Key result
Dasatinib exposure linked to cardiac tamponade, resolving after drug discontinuation.
Why the study?
Dasatinib, used for imatinib resistant or intolerant CML, has been reported to cause severe pericardial effusions, but drug-induced cardiac tamponade is rare.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
May signal dasatinib-related tamponade in resistant CML; leaves open optimal monitoring protocols.
Drug induced cardiac tamponade is rare. Therapy for imatinib resistant Chronic Myeloid Leukaemia (CML) is an emerging challenge in clinical haematology. For such cases treatment with second line tyrosine kinase inhibitors like dasatinib has resulted in improved outcomes. Dasatinib is a second line BCR-ABL tyrosine kinase inhibitor used in the treatment of Imatinib resistant or Imatinib intolerant CML. Dasatinib has been reported to cause severe pericardial effusions in 1% of all patients in clinical studies. We report here a case of Dasatinib induced cardiac tamponade in whom all other causes of pericardial effusion were excluded and whose clinical symptoms as well as effusion showed no recurrence one month after the drug was stopped.
No takes yet. Share an insight, caveat, or question.
Sushant Wattal (2017) conducted a case report in Chronic Myeloid Leukaemia / Cardiac tamponade (n=1). Dasatinib was evaluated on Recurrence of clinical symptoms and pericardial effusion. Dasatinib exposure was associated with the development of cardiac tamponade, with no recurrence of symptoms or effusion one month after discontinuation of the drug.
Synapse has enriched 10 related papers. Consider them for comparative context: